- Підписники
- Перегляди допису
- ER - коефіцієнт залучення
Триває завантаження даних...
Триває завантаження даних...
Dr. McCullough speaks with Laura Ingraham following Tony Fauci's day of testimony on Capitol Hill.
Moderna announced Wednesday that its experimental mRNA-based flu vaccine creates a better immune response against four influenza strains than the currently approved flu vaccine called Fluarix.
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes CAMBRIDGE, MA / ACCESSWIRE / May 31, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. The approval was granted under a breakthrough therapy designation and marks the second approved mRNA product from Moderna. "The FDA approval of our second product, mRESVIA, builds on the strength and versatility of our mRNA platform," said Stéphane Bancel, Chief Executive Officer of Moderna. "mRESVIA protects older adults from the severe outcomes of RSV infection, and it is the only RSV vaccine available in a pre-filled syringe designed to maximize ease of administration, saving vaccinators' time and reducing the risk of administrative errors. This
A precedent-setting ruling in favor of the First Amendment was issued today by the U.S. Court of Appeals for the Fifth Circuit. This influential Court established the right to object in court to censorship of […]
It's time to Be Intentional! Day 2 of Halt Hospital Homicide. Eye Witnesses of Crimes Against Humanity. Speakers of Truth!